7297-25-8 Usage
Uses
Used in Pharmaceutical Industry:
Eritrityl tetranitrate is used as a vasodilator for the treatment of various cardiovascular conditions, such as coronary artery disease and angina pectoris. It helps to improve blood flow and reduce the workload on the heart by dilating the blood vessels, thus providing relief from chest pain and other symptoms associated with these conditions.
Used in Coronary Applications:
Eritrityl tetranitrate is used as a coronary vasodilator to alleviate symptoms of coronary artery disease. It is particularly effective in treating acute episodes of chest pain and can be administered sublingually for rapid relief.
Used in Cardilate (Glaxo Wellcome):
Eritrityl tetranitrate is used as an active ingredient in the drug Cardilate, which is manufactured by Glaxo Wellcome. It is used for the treatment of angina pectoris and other cardiovascular conditions, providing relief from chest pain and improving blood flow to the heart.
Used in Research and Development:
Eritrityl tetranitrate is also used in the research and development of new pharmaceutical products and drug delivery systems. Its vasodilatory properties make it a valuable compound for studying the effects of nitrates on the cardiovascular system and for developing novel treatments for various heart-related conditions.
Hazard
Severe explosion risk when shocked or heated.
Purification Methods
Crystallise cordite from EtOH. It explodes on percussion at ~220-460o and is a vasodilator. [Beilstein 1 III 2358, 1 IV 2809.]
Check Digit Verification of cas no
The CAS Registry Mumber 7297-25-8 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 7,2,9 and 7 respectively; the second part has 2 digits, 2 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 7297-25:
(6*7)+(5*2)+(4*9)+(3*7)+(2*2)+(1*5)=118
118 % 10 = 8
So 7297-25-8 is a valid CAS Registry Number.
InChI:InChI=1/C4H6N4O12/c9-5(10)17-1-3(19-7(13)14)4(20-8(15)16)2-18-6(11)12/h3-4H,1-2H2
7297-25-8Relevant academic research and scientific papers
NITRATION EQUILIBRIUM IN THE MESO-ERYTHRITOL-AQUEOUS NITRIC ACID SYSTEM
Kazakov, A. I.,Lagodzinskaya, G. V.,Yunda, N. G.,Andrienko, L. P.,Korolev, A. M.,et al.
, p. 1966 - 1971 (2007/10/02)
Twelve equilibrium constants have been measured from 16 for sequential-parallel reactions in meso-erythritol nitration to the fully nitrated compound in aqueous HNO3.Free-energy changes during nitration of the aliphatic polyatomic alcohols, glycerol and meso-erythritol, are highest when diprimary dinitrates (NOON) and (NON) are produced.
Pharmaceutical composition and process of treatment
-
, (2008/06/13)
A process for alleviating proliferative skin diseases such as psoriasis, atopic dermatitis, etc. comprising administering to humans, or domesticated animals, topically and/or systemically a composition comprising a pharmaceutical carrier and at least one active compound selected from the groups, substituted alkyl zanthines, tricyclic antidepressants, organic nitrates, antihypertensives, anti-asthma agents and central nervous system depressants and combinations of certain compounds from specifically named groups of compounds.
